Prelude Capital Management, LLC Atea Pharmaceuticals, Inc. Transaction History

Prelude Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$2.8 - $3.35 $26,964 - $32,260	-9,630 Reduced 15.0%	54,578 $166,000
Q3 2023 Nov 14, 2023	BUY	$3.0 - $3.79 $120,390 - $152,092	40,130 Added 166.67%	64,208 $192,000
Q2 2023 Aug 14, 2023	SELL	$3.21 - $5.06 $14,194 - $22,375	-4,422 Reduced 15.52%	24,078 $90,000
Q1 2023 May 15, 2023	BUY	$3.0 - $4.97 $85,500 - $141,645	28,500 New	28,500 $95,000
Q2 2022 Aug 15, 2022	SELL	$5.33 - $8.18 $21 - $32	-4 Reduced 0.04%	10,196 $72,000
Q1 2022 May 16, 2022	BUY	$5.5 - $9.19 $56,100 - $93,738	10,200 New	10,200 $74,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $266M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.